Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/09/26 22:28:54」(JST)

wiki en

Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT₄ full agonist and 5-HT₃ antagonist.^[1]^[2] It also functions as a 5-HT_2B antagonist and has some affinity for the 5-HT_2A and 5-HT_2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.^[1]

Renzapride was being developed by Alizyme plc of the United Kingdom.

Clinical trials[edit]

Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.^[3]

References[edit]

^ ^a ^b Meyers NL, Hickling RI. (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.". Drugs R D. 9 (1): 37–63. PMID 18095752.
^ Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
^ "Results from Renzapride" (Press release). Alizyme plc. 23 April 2008. Retrieved 7 May 2009.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

English Journal

The safety of novel drugs used to treat irritable bowel syndrome.

Mozaffari S1, Nikfar S, Abdollahi M.
Expert opinion on drug safety.Expert Opin Drug Saf.2014 May;13(5):625-38. doi: 10.1517/14740338.2014.902932. Epub 2014 Mar 26.
INTRODUCTION: Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder with a high prevalence. Besides efficacy, the safety of each drugs used to treat GI disorders is an important issue in the drug development process.AREAS COVERED: This article reviews all Phase I to IV clinical
PMID 24669839

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients.

Mozaffari S1, Nikfar S2, Abdollahi M3.
Archives of medical science : AMS.Arch Med Sci.2014 Feb 24;10(1):10-18. Epub 2014 Feb 23.
INTRODUCTION: By targeting different subtypes of 5-hydroxytryptamine (5HT) receptors in the gastrointestinal (GI) tract, several drugs have been introduced for the management of irritable bowel syndrome (IBS). Renzapride is a full agonist for 5HT4 receptor and an antagonist to 5HT2b and 5HT3 recepto
PMID 24701208

Clinical trials in irritable bowel syndrome: a review.

Ervin CM1, Mangel AW.
Reviews on recent clinical trials.Rev Recent Clin Trials.2013 Mar;8(1):9-22.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. The specific bowel disturbances of diarrhea, constipation or an alternation between the two defines the IBS subtypes of diarrhea-pred
PMID 23130604

Japanese Journal

Affinity of Mosapride Citrate, a New Gastroprokinetic Agent,for 5-HT4 Receptors in Guinea Pig Ileum

YOSHIZAWA Takashi,YOSHIDA Naoyuki,MINE Yukiko,HOSOKI Kanoo
The Japanese journal of pharmacology 77(1), 53-59, 1998-05-01
… renzapride > …
NAID 10008680158

Related Pictures

GI-15 Non-neoplastic Diseases of the Small Figure imgf000011_0001 LINACLOTIDE:PHARMACOLOGY AND CLINICAL studied tegaserod 3 4 and renzapride 5 6 Renzapride hydrochloride, ATL-1251, AZM Renzapride (2008, 미국에서 임상 3상 Renzapride Alosetron Cilansetron Tegase

★リンクテーブル★

リンク元	「セロトニン受容体」

「セロトニン受容体」

Renzapride
Systematic (IUPAC) name
	4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]non-4-yl]-5-chloro-2-methoxybenzamide
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	109872-41-5
ATC code	None
PubChem	CID 3086547
IUPHAR ligand	244
ChemSpider	16736758
UNII	9073C0W4E9
ChEMBL	CHEMBL289753
Chemical data
Formula	C16H22ClN3O2
Mol. mass	323.818 g/mol
	SMILES Clc1cc(c(OC)cc1N)C(=O)N[C@@H]3CC[N@]2C[C@@H]3CCC2;
	InChI InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1 ; Key:GZSKEXSLDPEFPT-IINYFYTJSA-N ;
(what is this?) (verify);

　　[★]

英: serotonin receptor
同: 5-HT受容体
関: セロトニン